Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
DNTH
DNTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNTH News
Dianthus Therapeutics Launches $400 Million Public Offering
2h ago
seekingalpha
Liquidia and Dianthus See Active Options Trading
2h ago
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
3h ago
stocktwits
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
7h ago
Benzinga
Dianthus Achieves Key Milestones in CIDP Trial
8h ago
Benzinga
Dianthus Therapeutics Reports Q4 Earnings Miss
10h ago
seekingalpha
Dianthus Therapeutics Reports Interim Results from CAPTIVATE Trial
20h ago
NASDAQ.COM
Dianthus Announces CAPTIVATE Trial Interim Results Conference Call
1d ago
Newsfilter
Dianthus Announces Conference Call for CIDP Trial Results
1d ago
Yahoo Finance
Latham Group Shares Surge After Strong Q4 Results
5d ago
Benzinga
DNTH Options Analysis: $40 Put Contract Offers Attractive Yield Boost
Jan 16 2026
NASDAQ.COM
Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600
Jan 07 2026
Fool
Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600
Jan 07 2026
NASDAQ.COM
Dianthus and Leads Biolabs Initiate Phase 1 Trial of LBL-047
Dec 23 2025
Globenewswire
Options Trading for Dianthus Therapeutics (DNTH) in the First Week of August 2026
Dec 19 2025
NASDAQ.COM
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Nov 23 2025
Benzinga
Show More News
